"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

NEW!!! I-SPY PATIENT INFORMATION SITE. Visit: www.ispypatient.org

Featured News

Dr. Laura Esserman among recipients of 2020 Brinker Awards for Scientific Distinction Dr. Laura Esserman among recipients of 2020 Brinker Awards for Scientific Distinction

I-SPY in the News

October 1, 2020

Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial Members of the COVID R&D Alliance and Quantum Leap Healthcare Collaborative Enroll First Patients in I-SPY COVID Trial

Press Release

July 29, 2020

Quantum Leap Healthcare Collaborative Announces the Selection of Byondis' SYD985 in the I-SPY 2 TRIAL for Stage 2/3, High-Risk Breast Cancer Quantum Leap Healthcare Collaborative Announces the Selection of Byondis' SYD985 in the I-SPY 2 TRIAL for Stage 2/3, High-Risk Breast Cancer

Press Release

July 7, 2020

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.